AbbVie ABBV
SEC filings (XBRL) · quarterly · fiscal year ends December 31
Pick a second metric to compare.
Source: SEC EDGAR 10-Q/10-K XBRL, CIK 1551152; every value is traced to its filing on EDGAR. Retrieved Oct 11, 2026. Quarters labelled by fiscal quarter with the calendar period end. Q4 = annual minus Q1–Q3; cash-flow quarters derived from year-to-date figures.
Last 84 quarters
| Q3 2024Sep 30, 2024 | Q4 2024Dec 31, 2024 | Q1 2025Mar 31, 2025 | Q2 2025Jun 30, 2025 | Q3 2025Sep 30, 2025 | Q4 2025Dec 31, 2025 | Q1 2026Mar 31, 2026 | Q2 2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.5B | $15.1B | $13.3B | $15.4B | $15.8B | $16.6B | $15.0B | $17.0B |
| Operating income | $3.8B | −$1.5B | $3.7B | $4.9B | $1.9B | $4.5B | $4.0B | $6.4B |
| Net income | $1.6B | −$0.0B | $1.3B | $0.9B | $0.2B | $1.8B | $0.7B | $3.6B |
| Capital spending | $0.2B | $0.3B | $0.2B | $0.3B | $0.4B | $0.3B | $0.3B | $0.3B |
| Operating cash flow | $5.4B | $7.0B | $1.6B | $5.2B | $7.0B | $5.2B | $3.8B | $3.4B |
| Free cash flow | $5.2B | $6.8B | $1.4B | $4.9B | $6.6B | $4.9B | $3.6B | $3.1B |
| Capex / operating cash flow | 4.6% | 4.1% | 14.4% | 5.2% | 5.4% | 6.3% | 6.9% | 9.4% |
| Shares outstanding | 1.767B | 1.765B | 1.766B | 1.767B | 1.767B | 1.768B | 1.767B | 1.767B |
| Share count change, y/y | +0.1% | −0.1% | +0.0% | +0.0% | +0.0% | +0.2% | +0.0% | +0.0% |
| Diluted shares (weighted avg.) | 1.772B | — No figure for Q4 2024: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction. | 1.772B | 1.771B | 1.772B | — No figure for Q4 2025: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction. | 1.774B | 1.771B |
— Diluted shares (weighted avg.): No figure for Q4 2024: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction.
— Diluted shares (weighted avg.): No figure for Q4 2025: Fiscal Q4: the 10-K gives only the 12-month weighted average; a quarterly weighted average cannot be derived by subtraction.
Diluted shares (weighted avg.): fiscal Q4 is blank because the 10-K gives 12-month figures only.
XBRL tags used
| Revenue | SalesRevenueNet | Mar 2013 to Mar 2014 |
|---|---|---|
Revenues | Jun 2014 to Sep 2014 | |
SalesRevenueNet | Dec 2014 to Dec 2014 | |
Revenues | Mar 2015 to Sep 2015 | |
SalesRevenueNet | Dec 2015 to Dec 2015 | |
Revenues | Mar 2016 to Jun 2026 | |
| Operating income | OperatingIncomeLoss | Mar 2013 to Jun 2026 |
| Net income | NetIncomeLoss | Mar 2015 to Jun 2026 |
| Capital spending | PaymentsToAcquirePropertyPlantAndEquipment | Mar 2013 to Jun 2026 |
| Operating cash flow | NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Mar 2013 to Dec 2015 |
NetCashProvidedByUsedInOperatingActivities | Mar 2016 to Jun 2026 | |
| Free cash flow | ocf - capex: NetCashProvidedByUsedInOperatingActivitiesContinuingOperations, PaymentsToAcquirePropertyPlantAndEquipment | Mar 2013 to Dec 2015 |
ocf - capex: NetCashProvidedByUsedInOperatingActivities, PaymentsToAcquirePropertyPlantAndEquipment | Mar 2016 to Jun 2026 | |
| Capex / operating cash flow | capex / ocf * 100: PaymentsToAcquirePropertyPlantAndEquipment, NetCashProvidedByUsedInOperatingActivitiesContinuingOperations | Mar 2013 to Dec 2015 |
capex / ocf * 100: PaymentsToAcquirePropertyPlantAndEquipment, NetCashProvidedByUsedInOperatingActivities | Mar 2016 to Jun 2026 | |
| Shares outstanding | dei:EntityCommonStockSharesOutstanding | Mar 2013 to Jun 2026 |
| Diluted shares (weighted avg.) | WeightedAverageNumberOfDilutedSharesOutstanding | Mar 2013 to Jun 2026 |
Where a company changed tags, each quarter uses the tag it was reported under; the newest tag is primary.